Scroll To Top

To Treat or Not to Treat?

To Treat or Not to Treat?

Bowers_26

Every few months I have a patient who has just picked up HIV and is acutely seroconverting'what's called primary infection. Sometimes the patient comes in with a suspicious set of viral symptoms: fever, swollen glands, viral rash, etc. But sometimes the patient merely has a history of high-risk exposure and is asymptomatically seroconverting. When antibody tests come back positive, I do some counseling and reassure patients about the manageability of HIV in the 21st century; then I move on to a theoretical discussion. Should we start treatment right away? Various treatment guidelines around the world recommend waiting to start antiretrovirals until a CD4-cell count is, depending on location, below 200'350, or a viral load is above 55,000'100,000. It should typically take about 10 years before a patient's numbers reach those ranges. However, some decline more rapidly and could need treatment in three to five years. Others are slow progressors and might not need treatment for 12 to 15 years. About 1% are the long-term nonprogressors, who still have not needed treatment after more than 20 years of seropositivity. There is no way to initially tell who is going to be a rapid or a slow progressor. However, we do know that after the initial burst of HIV replication and rapid rise in viral load, the immune system will kick in and bring down the viral load. And after four to six months the viral load is at a steady state'the set point. The lower the set point, the longer the patient will go before needing treatment. But several questions arise: Would immediate suppression of that viral burst by a short course of antiretrovirals improve the chances of a low set point? If the antivirals were continued, would there be a better chance of eradication sometime in the future when new therapies become available? Is there harm in trying this? The answer to the first question is no. Although several years ago there was evidence that early treatment preserved HIV-specific immune responses, giving better viral control'that is, a low set point'long-term follow-up has shown that this benefit is not maintained. After being off treatment for one year, patients who received early treatment had viral loads and CD4 cells in the same ranges as patients who were not initially treated. Preserving future eradication potential is a more interesting question, though. There is no evidence that immediate treatment can prevent HIV infection of the resting CD4-cell reservoir, which appears to be infected within 48 hours of the first symptoms of HIV. However, it does appear that early treatment can reduce the size of the infected reservoir. This might be reflected in one study that showed fewer blips in viral load measurements in patients who had early treatment when compared to those who started treatment later. Another study used an ultrasensitive viral load test to compare early versus late treatment. Viral loads of less than three were found among early treaters, compared to none in that range in the late treaters. What we don't know is whether these indicators of profound viral suppression translate into better long-term viral control. Early treatment does preserve a more homogeneous viral population. This happens because HIV continually mutates as it replicates. So the longer you wait to suppress HIV, the more variation there is in the HIV that is created. Theoretically'and I emphasize theoretically'future types of vaccine or antibody treatments might work better on a homogeneous population of HIV. But there is a downside to this particular approach. Because viral loads are often very high in primary infection, there is some concern about provoking antiretroviral resistance with one short course of treatment. But the long-term side effects, such as lipodystrophy, would not be an issue in that case. This does become an issue, of course, if early treatment is continued in the hope of increasing future eradication. As is so often the case in HIV medicine, there is no clear answer. The best recommendation is to refer acute seroconverters to any studies of early treatment strategies that are available in your area. If we can get some answers from these studies, then we won't need another one of these 'what if' discussions. Bowers is board-certified in family practice and is a senior partner with Pacific Oaks Medical Group, one of the largest U.S. practices devoted to HIV care. E-mail him at dan@hivplusmag.com.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.